4.7 Article

Management bundles for candidaemia: the impact of compliance on clinical outcomes

期刊

JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
卷 70, 期 2, 页码 587-593

出版社

OXFORD UNIV PRESS
DOI: 10.1093/jac/dku414

关键词

candidiasis; guidelines; intravenous catheters; invasive disease; fungal infections

资金

  1. Pfizer Japan Inc.
  2. MSD K.K.
  3. Astellas Pharma Inc.
  4. Dainippon Sumitomo Pharma
  5. Shionogi Co., Ltd
  6. Takeda Pharmaceutical Co., Ltd
  7. Daiichi Sankyo Co., Ltd
  8. Meiji Seika Pharma Co., Ltd
  9. Taisho Toyama Pharmaceutical Co., Ltd
  10. Chugai Pharmaceutical Co., Ltd
  11. AstraZeneca
  12. Eisai Co., Ltd
  13. Otsuka Pharmaceutical Co., Ltd
  14. Ono Pharmaceutical Co., Ltd
  15. Taiho Pharmaceutical Co.
  16. Boehringer Ingelheim
  17. Toyama Chemical Co., Ltd
  18. Shionogi Co., Ltd.

向作者/读者索取更多资源

Objectives: The Mycoses Forum in Japan has developed management bundles for candidaemia to incorporate into bedside practice. The aim of this study was to investigate nationwide compliance with the bundles and their impact on clinical outcomes. Methods: Non-neutropenic patients treated with antifungals for candidaemia were surveyed. Bundles consist of nine items to complete. Data were sent to the central office between July 2011 and April 2012. Results: Six hundred and eight patients were analysed. The compliance rate for achieving all elements was 6.9%, and it increased to 21.4% when compliance was analysed by the bundle except for oral switch. There was a significant difference in clinical success between patients with and without compliance [92.9% versus 75.8% (P = 0.011)]. Compliance with the bundles, however, failed to be an independent factor associated with favourable outcomes. When step-down oral therapy was excluded from the elements of compliance, compliance with the bundles was revealed to be an independent predictor of clinical success (OR 4.42, 95% CI 2.05-9.52) and mortality (OR 0.27, 95% CI 0.13-0.57). Independent individual elements contributing to clinical success were removal of central venous catheters within 24 h, assessment of clinical efficacy on the third to the fifth day and at least 2 weeks of therapy after clearance of candidaemia. Conclusions: Compliance with the bundles for candidaemia had a beneficial effect on clinical outcomes. Promotion of the bundles approach may have the potential to narrow the gap between clinical evidence and bedside practice.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据